SCHEMBL1967101

SCHEMBL1967101

Oc1ccc2cccc(F)c2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 1/20 0.42
KDM4E B2RXH2 7/20 0.41
MAPT P10636 5/20 0.41
NPC1 O15118 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
LMNA P02545 4/20 0.41
RAB9A P51151 3/20 0.41
KMT2A Q03164 3/20 0.41
HTT P42858 2/20 0.41
AR P10275 1/20 0.40
METAP2 P50579 2/20 0.39
PLAU P00749 1/20 0.39
NCF1 P14598 1/20 0.39
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
CYP3A4 P08684 2/20 0.38
HIF1A Q16665 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX12 P18054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL672744 0.77 METAP2 (0.63) KDM4EMAPTNPC1SMN1; SMN2LMNA
SCHEMBL30082244 0.77 METAP2 (0.63) KDM4EMAPTNPC1SMN1; SMN2LMNA
SCHEMBL931153 0.77 SMN1; SMN2 (0.42) PFKFB3KDM4EMAPTNPC1SMN1; SMN2
SCHEMBL15442576 0.76 METAP2 (0.61) KDM4EMAPTNPC1SMN1; SMN2LMNA
SCHEMBL8467827 0.76 METAP2 (0.61) KDM4EMAPTNPC1SMN1; SMN2LMNA
SCHEMBL6540982 0.76 METAP2 (0.61) KDM4EMAPTNPC1SMN1; SMN2LMNA
SCHEMBL413180 0.76 METAP2 (0.61) KDM4EMAPTNPC1SMN1; SMN2LMNA
Ammonia Solution, Strong SCHEMBL3284067 0.76 METAP2 (0.61) KDM4EMAPTNPC1SMN1; SMN2LMNA
SCHEMBL1496246 0.76 METAP2 (0.61) KDM4EMAPTNPC1SMN1; SMN2LMNA
SCHEMBL16444064 0.76 METAP2 (0.61) KDM4EMAPTNPC1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987251-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-03-24 US disclosed
US-20140045817-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-02-13 US disclosed
US-8575145-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-11-05 US disclosed
EP-2334677-B1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2013-10-09 EP disclosed
EP-2334677-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS Array Biopharma, Inc. (US) 2011-06-22 EP disclosed
US-20110144085-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-16 US disclosed
WO-2010022076-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-02-25 WO disclosed
EP-0317188-B1 Heteroaromatic enamide derivatives and their use as pesticides ROUSSEL UCLAF (FR) 1995-09-27 EP disclosed
US-5114940-A Insecticides or anthelmintics from fused ring heterocycles containing amides or thioamides ROUSSEL-UCLAF (FR) 1992-05-19 US disclosed
EP-0317188-A2 Heteroaromatic enamide derivatives and their use as pesticides ROUSSEL UCLAF (FR) 1989-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144085-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 PFKFB3 1520/4885KDM4E 1354/4885MAPT 3648/4885
US-20140045817-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM2, PIM1, PIM3 PFKFB3 687/4885KDM4E 1107/4885MAPT 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.